Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;192(3):1041-1049.
doi: 10.1007/s11845-022-03093-9. Epub 2022 Jul 13.

Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer

Chunyu Tian  1 , Minghui Wang  1 , Hancheng Liu  1 , Jianping Liu  1 , Mengze Xu  2 , Lihui Ma  3
Affiliations

Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer

Chunyu Tian et al. Ir J Med Sci. 2023 Jun.

Abstract

Objective: Pyrotinib is a novel EGFR/HER2 dual tyrosine kinase inhibitor developed in China, while its role in neoadjuvant therapy of HER2-positive (HER2+) breast cancer lacks evidence. The current study aimed to explore the efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide (TAC) for HER2+ breast cancer.

Methods: A total of 27 HER2+ breast cancer patients received neoadjuvant pyrotinib plus TAC for 6 cycles, then surgery was performed. The clinical and pathological responses, and adverse events were evaluated.

Results: Complete response rate, objective response rate, and disease control rate were 0.0%, 44.4% and 100.0% after 2 treatment cycles; 0.0%, 37.0%, and 100.0% after 4 treatment cycles; 37.0%, 37.0%, and 96.3% after 6 treatment cycles; as well as 37.0%, 44.4%, and 100.0% based on the best clinical response. Regarding pathological response, there were 1 (2.7%), 3 (11.1%), 8 (29.6%), 5 (18.5%), and 10 (37.0%) patients realizing Miller-Payne grade (G) 1, G2, G3, G4, and G5, respectively; besides, 10 (37.0%) patients achieved total pathological complete response (pCR), 10 (37.0%) patients realized pCR in breast, and 23 (85.2%) patients achieved pCR in lymph node. Additionally, adverse events included diarrhea (81.5%), dental ulcer (7.4%), and hand-foot syndrome (3.7%); meanwhile, grade 3-4 adverse event consisted of only diarrhea (11.1%).

Conclusion: Neoadjuvant pyrotinib plus TAC treatment is efficient and safe in HER2+ breast cancer patients, while further validation is needed.

Keywords: HER2+ breast cancer; Neoadjuvant therapy; Pathological response; Pyrotinib; TAC.

PubMed Disclaimer

References

    1. Trayes KP, Cokenakes SEH (2021) Breast cancer treatment. Am Fam Physician 104(2):171–178 - PubMed
    1. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics. CA Cancer J Clin 70(1):7–30. https://doi.org/10.3322/caac.21590 - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
    1. Martinez-Saez O, Prat A (2021) Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract 17(10):594–604. https://doi.org/10.1200/OP.21.00172 - DOI - PubMed
    1. Pernas S, Tolaney SM (2022) Clinical trial data and emerging strategies: HER2-positive breast cancer. Breast Cancer Res Treat 193(2):281–291. https://doi.org/10.1007/s10549-022-06575-7 - DOI - PubMed

MeSH terms

LinkOut - more resources